Latest "Research News" Posts
The Myocarditis Foundation is pleased to announce that Dr. Guobao Chen, PhD, is the 2016 Fellowship Grant Recipient for the 2107-2018 Academic Year. Dr. Chen was the second place finalist in last year’s Fellowship Grant applicants, but came in above all the others in the 2016 submissions.
Dr. Chen is from Johns Hopkins University School of Medicine and his mentor is Dr. Daniela Cihakova MD, PhD. Dr. Cihakova was the very first MF Fellowship Grant recipient in 2006. Dr. Chen is now conducting myocarditis research in Dr. Cihakova’s Lab and his research submission is entitled: “The Role of PDGFRa+ Cardiac Fibroblast in Myocarditis.”
The Myocarditis Foundation is proud to announce that Katelyn Bruno, our Assistant Secretary of the Board and Director of Communications for the Myocarditis Foundation is now Dr. Katelyn Bruno, PhD!
Yes, another Researcher in the field of Myocarditis!
Dr. Bruno has been working with the Myocarditis Foundation for 4 years while working on her Doctorate in Environmental Health Sciences at John’s Hopkins University Bloomberg School of Public Health. Her thesis was on “The Effect of Environmentally-derived Sex Steroids on Coxsackievirus B3 Myocarditis: Focus on Vitamin D and Bisphenol A”.
Dr. Bruno became involved with the Myocarditis Foundation in 2012 when she was appointed Director of Communications by the Board of Directors and began getting involved in several ways with the Foundation.
The year 2016 may have just begun, but Dr. Leslie Cooper is already scheduled to speak at many various conferences around the world on Myocarditis. This one in particular, “The International Society of Cardiomyopathies and Heart Failure” (ISCHF) will be in Kyoto, Japan, December 2-4, 2016. The theme of the ISCHF 2016 is Prevention, Diagnosis, and Treatment.
The ISCHF, established in 2007, has held regional and international congresses, and established working groups and task-forces to facilitate much-needed cooperative research in these fields among their members worldwide and with other societies and related groups in the fields of cardiomyopathies and heart failure.
We all know what we think of when we hear of a sudden death in a young athlete…
Dr. Cooper shared an article on “Sports-Related Sudden Death in the General Population” and a slide within it on how much Cardiovascular Sudden Death is unexplained. 78% of Sudden Death is unexplained! (link contains full article)
The study in the paper, was conducted in France. It revealed a much higher prevalence of sports related Sudden Death in the general population than previously suspected (estimated at approximately 4250 cases in the United States or 800 cases in France each year in the 10 to 75 year old age group), which they certainly viewed as an underestimate.
Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities
Dr. Leslie Cooper, who co-authored this paper, shared this with us for you to read.
In a paper published in an American Heart Association Journal, in 2015, there are general considerations to consider before resuming competitive sports. I will try and summarize the myocarditis section of it here, but for the complete article, please click here.
Myocarditis commonly presents with severe shortness of breath on exertion, chest pain and cardiac arrhythmias. It can also present as a myocardial infarction-like syndrome (Heart Attack), with sudden death in the presence of normal coronary arteries.
Dr. Leslie Cooper shared this with us and asked that we post it for our followers.
This Doctoral Dissertation from November 2015, studied Cardiac Sarcoidosis (CM) and Giant Cell Myocarditis (GCM) in Finland.
The researcher, Riina Kandolin, at the Division of Cardiology, Heart and Lung Center at Helsinki University Hospital, has found the detection rate of CS and GCM in Finland is increasing and the prognosis with contemporary diagnostic and therapeutic methods seems better than previously reported.
Please enjoy this Abstract on her work. For the complete Dissertation, please refer to full article
Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) are underdiagnosed inflammatory myocardial diseases.
The Myocarditis Foundation is pleased to announce that it will be funding a research fellowship grant for the 2016/2017 grant cycle. The Myocarditis Foundation will be awarding the research grant to Dr. Jon Sin of Cedars-Sinai Medical Center in the amount of $40,000. Dr. Sin is under the mentorship of Dr. Ralph Feuer of Cedars-Sinai Medical Center.
The Myocarditis Foundation, an international non-profit organization founded in 2005, is dedicated to increasing awareness and hastening progress in understanding this rare disease. Myocarditis is a disease that is marked by inflammation and scarring of the heart muscle, which can progress rapidly to heart failure and death or heart transplantation.
During the 2015 Family Support Meeting several prominent physicians specializing or studying myocarditis gave presentations to the attendees to help them understand myocarditis and the advances in diagnostics and treatment over the years. The speakers include Dr. Leslie Cooper, Dr. Jack Price, Dr. Colan, Dr. McNamara and Dr. Bode. See some key points each speaker made in this blog post.
Dr. Cooper is Chief of Cardiology at Mayo Clinic in Jacksonville, Florida. He is the world’s leading expert in myocarditis and Co-Founder and Board Member of the Myocarditis Foundation.
- The purpose of Dr. Cooper’s talk was to give the attendees hope on where we have been and where we are today as the Myocarditis Foundation
- In 1837, “Myokarditis” was first termed in Germany as inflammatory heart muscle disease secondary to heart muscle cells being destroyed
- Over the next 100 years very little was said about myocarditis, though it was associated with rheumatic fever and syphilis around World War I
- The proportion of heart failure caused my myocarditis peaks at < 1 month of age, drops down but resurges again at puberty.
Inflammation refers to immune cells and proteins released into the bloodstream by immune cells, like CRP and IL-6 which are used by clinicians as an indicator of inflammation. CRP and IL-6 are measured in the blood (i.e., sera). Myocarditis is defined by the presence of inflammation or immune cells in the heart muscle, called myocardium, by histology when a heart biopsy is obtained. Research in animal models has revealed that it is not just the presence of inflammation that causes a problem leading to heart failure, but it depends on the “type” of inflammation in the heart. There are many types of immune cells and some of them are good at fighting off infections like the viral infections that commonly cause myocarditis, and so are “protective”.
Myocarditis contributes to the global burden of cardiovascular disease primarily through sudden death and dilated cardiomyopathy, and the contribution of myocarditis as a cause of sudden death is most likely underestimated. For example, in Japan, the rate of myocarditis was estimated from an unselected national registry of 377,841 autopsies. 434 of these cases (0.11% or about 1:1000) had idiopathic, interstitial, viral, or non-specific myocarditis. In contrast, the rate of myocarditis was 3% (six of 200) in autopsies of sudden death patients in Japan. However, of 97 (77 male, 20 female) school children who experienced sudden death in Kanagawa prefecture, 3 of the 18 (16.6%) with histologically established cardiovascular disease had myocarditis.